Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIXT Bioxytran	$0.08 -8.1%	$0.09	$0.06 ▼ $0.23	$7.46M	1.78	108,197 shs	150,290 shs
CASI CASI Pharmaceuticals	$2.43 +3.0%	$1.57	$1.09 ▼ $7.67	$29.02M	0.63	3.73 million shs	110,230 shs
MIRA MIRA Pharmaceuticals	$1.42 -0.7%	$1.44	$0.73 ▼ $2.70	$27.27M	1.77	312,425 shs	138,312 shs
TENX Tenax Therapeutics	$5.92 -1.3%	$5.94	$3.25 ▼ $7.89	$27.38M	1.46	20,765 shs	64,087 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIXT Bioxytran	0.00%	+4.75%	-2.56%	-44.72%	-5.74%
CASI CASI Pharmaceuticals	0.00%	-0.84%	+59.46%	+26.20%	-63.41%
MIRA MIRA Pharmaceuticals	0.00%	-4.67%	-17.34%	+17.21%	-22.70%
TENX Tenax Therapeutics	0.00%	+0.50%	-0.83%	-0.83%	+42.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIXT Bioxytran	0.6581 of 5 stars	0.0	5.0	0.0	0.6	1.7	0.0
CASI CASI Pharmaceuticals	3.6769 of 5 stars	3.5	3.0	4.3	0.6	1.7	0.0
MIRA MIRA Pharmaceuticals	3.0026 of 5 stars	3.8	5.0	0.0	2.2	0.0	0.6
TENX Tenax Therapeutics	1.4551 of 5 stars	3.6	1.0	0.0	1.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIXT Bioxytran	0.00	N/A	N/A	N/A
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	64.61% Upside
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,097.18% Upside
TENX Tenax Therapeutics	3.25	Buy	$17.00	187.16% Upside

Current Analyst Ratings Breakdown

Latest BIXT, TENX, MIRA, and CASI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIXT Bioxytran	N/A	N/A	N/A	N/A	($0.02) per share	N/A
CASI CASI Pharmaceuticals	$28.54M	1.05	N/A	N/A	$0.12 per share	20.25
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$26.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIXT Bioxytran	-$2.37M	-$0.03	N/A	∞	N/A	N/A	N/A	-1,577.96%	N/A
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/29/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.49	N/A	N/A	N/A	N/A	-406.70%	-328.44%	11/11/2025 (Estimated)
TENX Tenax Therapeutics	-$17.60M	-$0.92	N/A	N/A	N/A	N/A	-31.34%	-30.39%	11/12/2025 (Estimated)

Latest BIXT, TENX, MIRA, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	N/A	CASI CASI Pharmaceuticals	-$0.47	N/A	N/A	N/A	$6.28 million	N/A
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
8/13/2025	Q2 2025	TENX Tenax Therapeutics	-$0.50	-$0.27	+$0.23	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIXT Bioxytran	N/A	N/A	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIXT Bioxytran	N/A	N/A	N/A
CASI CASI Pharmaceuticals	N/A	0.81	0.68
MIRA MIRA Pharmaceuticals	N/A	2.80	2.80
TENX Tenax Therapeutics	N/A	41.89	41.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIXT Bioxytran	N/A
CASI CASI Pharmaceuticals	22.23%
MIRA MIRA Pharmaceuticals	35.16%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
BIXT Bioxytran	70.00%
CASI CASI Pharmaceuticals	21.24%
MIRA MIRA Pharmaceuticals	6.65%
TENX Tenax Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIXT Bioxytran	2	88.99 million	26.70 million	Not Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable
TENX Tenax Therapeutics	9	4.56 million	4.39 million	Not Optionable

BIXT, TENX, MIRA, and CASI Headlines

Recent News About These Companies

Leerink Partnrs Has Negative Forecast for TENX Q3 Earnings

August 19, 2025 | americanbankingnews.com

William Blair Brokers Decrease Earnings Estimates for TENX

August 19, 2025 | americanbankingnews.com

Q3 EPS Estimate for Tenax Therapeutics Reduced by Analyst

August 18, 2025 | americanbankingnews.com

Equities Analysts Set Expectations for TENX FY2028 Earnings

August 17, 2025 | americanbankingnews.com

Tenax Posts Wider Loss in Fiscal Q2

August 14, 2025 | aol.comA

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

August 14, 2025 | msn.com

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

TENX Tenax Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | globenewswire.com

Tenax Therapeutics Inc.

May 9, 2025 | barrons.com

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

April 16, 2025 | seekingalpha.com

Tenax Therapeutics files to sell 4.14M shares of common stock for holders

April 16, 2025 | markets.businessinsider.com

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

Tenax Therapeutics reports Q4 EPS (18c), consensus (43c)

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics (TENX) Gets a Buy from William Blair

March 27, 2025 | markets.businessinsider.com

Tenax Therapeutics: Q4 Earnings Snapshot

March 25, 2025 | timesunion.comT

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 25, 2025 | globenewswire.com

Tenax Therapeutics Inc TENX

March 14, 2025 | morningstar.comM

Roth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)

March 6, 2025 | markets.businessinsider.com

Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103

March 5, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BIXT, TENX, MIRA, and CASI Company Descriptions

Bioxytran OTCMKTS:BIXT

$0.08 -0.01 (-8.11%)

As of 03:07 PM Eastern

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

CASI Pharmaceuticals NASDAQ:CASI

$2.43 +0.07 (+2.97%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 -0.03 (-1.40%)

As of 07:47 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.42 -0.01 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.43 +0.01 (+0.70%)

As of 07:58 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Tenax Therapeutics NASDAQ:TENX

$5.92 -0.08 (-1.33%)

Closing price 04:00 PM Eastern

Extended Trading

$5.92 0.00 (0.00%)

As of 04:20 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time